G92.04
Immune effector cell-associated neurotoxicity syndrome, grade 4
Clinical Classification Guidelines
Inclusion Terms
- ICANS, grade 4
Medical Intelligence & Overview
Grade 4 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a severe neurological complication that can occur after certain cancer treatments involving immune effector cells, such as CAR T-cell therapy. This condition indicates life-threatening symptoms with significant neurological impairment, requiring immediate medical attention. Accurate diagnosis and prompt management are essential to improve outcomes and minimize long-term effects.
Causes & Symptoms
Clinical Causes: Administration of immune effector cell therapies, especially chimeric antigen receptor (CAR) T-cell therapy The immune response triggered by these therapies targeting cancer cells Inflammatory processes resulting from cytokine release syndrome (CRS), which often precedes or accompanies ICANS Underlying patient factors such as pre-existing neurological conditions or immune system status
Key Symptoms: Severe mental status changes, including confusion or disorientation Seizures or abnormal movements Loss of consciousness or coma Severe headache or cerebral edema signs High fever and neurological deterioration Weakness or paralysis in limbs Sensory deficits or visual disturbances
Diagnostic & Treatment
Diagnosis Path: Neurological examination revealing profound deficits Imaging studies such as MRI or CT scans to rule out other causes Electroencephalogram (EEG) to identify seizure activity Laboratory tests indicating systemic inflammation or cytokine levels Exclusion of other neurological conditions or infections
Treatment Protocols: Intensive monitoring of neurological status Administration of corticosteroids to reduce cerebral inflammation Use of anti-seizure medications to control seizures Supportive measures such as mechanical ventilation if respiratory compromise occurs Management of cytokine release syndrome symptoms Evaluation and treatment of intracranial pressure if applicable Collaborative care involving neurologists, oncologists, and intensive care specialists
Clinical Advice & FAQs
Billing Guidance
Is G92.04 a billable ICD-10 code?
Yes, G92.04 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G92.04?
Clinical documentation must specify the nature of Immune effector cell-associated neurotoxicity syndrome, grade 4 and any associated comorbidities for accurate reporting.
Cite this Clinical Reference